RegulatoryFlynn Pharma and Pfizer fined 70M pounds for substantial...

Flynn Pharma and Pfizer fined 70M pounds for substantial price jump on epilepsy drug

-

The ongoing tale of the CMA (Competition and Markets Authority) investigation on Flynn Pharma and Pfizer has reached a verdict in terms of a fine. The two companies are to pay a collective fine of £70M, or $80.61M. According to the U.K. antitrust authorities, the companies took advantage of a loophole to vastly increase prices.

Pfizer Inc. is one of the most prominent North-American multinational companies in the pharmaceutical industry. The company is a biotechnological organization that operates out of Manhattan, New York and was founded in 1849, 173 years ago. The company aims to produce revolutionary medications that elongate the lives of patients suffering from various diseases. The company’s current stock price is just over $51 per share.

Flynn Pharma Ltd. is a pharmaceutical company founded in 2006 that is located in Hertfordshire, United Kingdom. The company operates as a holding company with multiple subsidiaries that indulge in the distribution of pharmaceutical products. It aids the acquisition, development and commercialisation of medicinal products for the secondary healthcare market.

The Competition and Markets Authority (CMA) claims that Pfizer and Flynn Pharma de-branded Epanutin, the epilepsy drug, to steer clear of the regulations, which led to the hikes in the price of between 8.8 times to 17 times the original price. The prices further increased when the drug was supplied to Flynn Pharma, which took it up to 20 times higher than the original price. The difference between the prices paid for the product within a span of a year was astronomical. According to authorities, NHS (National Health Service) in 2012, paid £2M for Epanutin, while in 2013, they paid £50M, which is a hefty increase of 2400% for just a single year (25 times the original price).

Latest news

A new blood test reveals an early ovarian cancer risk

Early Detection of Ovarian Precancer via Blood Marker The level of CA125 is raised in the blood during ovarian cancer....

According to sources, the US FDA shelving commissioner’s voucher scheme for quick drug reviews

FDA Shelves Fast-Track Drug Voucher Program Former U.S. Food and Drug Administration Commissioner Marty Makary's fast-track drug review program, launched...

Top 10 Technologies Transforming Pharmaceutical Facility Design

Executive Summary Pharmaceutical facility design is evolving as manufacturers respond to increasingly complex production requirements, stricter regulatory expectations, supply chain...

Must read

Surrounded by controversy, FDA approves Biogen’s Alzheimer’s drug Aduhelm

In the middle of the debate about the Alzheimer’s drug approval, the United States FDA has authorized Aduhelm

You might also likeRELATED
Recommended to you